GlassScriptPhysician profile
Stanton Hugger
NPI 1881053437
$10,456.15
in general payments reported to CMS, 2019-2025
17 companies · $7,906 in 2025
The $7,906 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,415 · 2024: $1,135 · 2025: $7,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Travel and Lodging: $3,003 · Food and Beverage: $2,945 · Education: $8.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Travel and Lodging | $3,002.99 |
| Food and Beverage | $2,944.62 |
| Education | $8.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,260.76 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $528.85 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $272.72 | 2023-2024 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $268.47 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $220.02 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tempus Ai, INC | $207.24 | 2024 | |
| Idorsia Pharmaceuticals US INC | $161.12 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $140.42 | 2024-2025 | Cobenfy |
| Biogen, INC. | $114.40 | 2024 | Zurzuvae |
| Alkermes, INC. | $110.06 | 2023-2024 | Aristada, Lybalvi |
| Tris Pharma INC | $36.28 | 2024 | Dyanavel Xr |
| Almatica Pharma LLC | $34.50 | 2024-2025 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.76 | 2023 | |
| Noven Therapeutics, LLC | $23.21 | 2023 | Xelstrym |
| Neos Therapeutics, LP | $17.59 | 2024 | Adzenys Xr-Odt |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $16.13 | 2024 | |
| Supernus Pharmaceuticals, INC. | $15.62 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanton Hugger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.